The Column Group
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies. The firm will invest in 10-12 disease-focused drug discovery companies per fund, each with the potential to become a leader in their respective fields. These companies will be strongly supported by the unique and complementary skill sets of the team, which includes prominent authorities in the scientific, operational and financial arenas. The Column Group seeks to partner with exceptional scientific founders, entrepreneurs, executives and investment organizations that share the vision for building the next generation of drug discovery and development companies.

Prospect Venture Partners
Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biopharmaceutical and medical device companies. With more than $1 billion of capital under management, the firm supports innovative companies at all stages of development – from seed to growth – and offers a broad network of resources for entrepreneurs. The firm seeks to partner with exceptional teams committed to excellence and innovation.

Rho Ventures
Rho is a diversified private equity firm dedicated to providing exceptional results for its investors. Since 1981 Rho Ventures has been investing in leading edge, high growth companies that redefine the status quo. The firm has a deep history of supporting companies at multiple stages of growth spanning early stage investments to later stage expansion and growth equity transactions. Rho Ventures has financed approximately 200 companies and has invested in market leaders across many high growth sectors, including information technology, communications, new media, healthcare and energy technology.

Takeda Ventures
Takeda Ventures, Inc. (TVI) is the corporate venture arm of Takeda Pharmaceutical Company Limited (TPC), a world-class pharmaceutical company and the largest in Japan. TVI now assumes the role of Takeda’s former venture investment group, Takeda Research Investment, Inc., and remains a wholly owned subsidiary of Takeda America Holdings, Inc. The new group continues to seek strategic opportunities to complement and extend internal discovery capabilities, but will additionally explore potentially new business avenues for Takeda through external strategic venture activities. The group’s aim is to encourage and support therapeutic innovation in the biopharmaceutical sector, as well as academic centers of excellence, through early stage capital investment and provision of access to the resources of a multinational pharmaceutical company.

Tichenor Ventures
Tichenor Ventures is the investment vehicle for McHenry (Mac) T. Tichenor, Jr., a private investor, entrepreneur and philanthropist with broad experience in managing and growing successful businesses. Mr. Tichenor served as President, Chief Executive Officer and Director of Tichenor Media System, Inc., which he subsequently merged with the Hispanic Broadcasting Corporation and, ultimately, with Univision Communications. He has also served as a director of several public companies. Mr. Tichenor is currently Executive Director of WWWW Foundation (Quad W), a non-profit organization devoted, in part, to cancer research. He is active on various corporate and university boards, including Belo Corp., the McCombs School of Business Advisory Council at the University of Texas at Austin and the MD Anderson Cancer Center Board of Visitors.